These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 10645781)
1. Antisense therapeutics in oncology: points to consider in their clinical evaluation. Mani S; Gu Y; Wadler S; Fingert H Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):543-7. PubMed ID: 10645781 [TBL] [Abstract][Full Text] [Related]
2. Making sense of antisense. Vidal L; Blagden S; Attard G; de Bono J Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851 [TBL] [Abstract][Full Text] [Related]
3. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review). Kim R; Tanabe K; Emi M; Uchida Y; Toge T Int J Oncol; 2004 Jan; 24(1):5-17. PubMed ID: 14654935 [TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide technology in the development of cancer therapeutics. Tseng BY; Brown KD Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240 [No Abstract] [Full Text] [Related]
5. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential. Olie RA; Zangemeister-Wittke U Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155 [TBL] [Abstract][Full Text] [Related]
7. Antisense therapy in malignant diseases: status quo and quo vadis? Tamm I Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947 [TBL] [Abstract][Full Text] [Related]
8. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Frankel SR Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157 [TBL] [Abstract][Full Text] [Related]
9. Antisense therapy for cancer. Gleave ME; Monia BP Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854 [TBL] [Abstract][Full Text] [Related]
11. Antisense therapy in oncology: new hope for an old idea? Tamm I; Dörken B; Hartmann G Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935 [TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides as therapeutics for malignant diseases. Ho PT; Parkinson DR Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689 [TBL] [Abstract][Full Text] [Related]
14. Nucleic-acid therapeutics: basic principles and recent applications. Opalinska JB; Gewirtz AM Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257 [TBL] [Abstract][Full Text] [Related]
15. Antisense therapeutics: is it as simple as complementary base recognition? Agrawal S; Kandimalla ER Mol Med Today; 2000 Feb; 6(2):72-81. PubMed ID: 10652480 [TBL] [Abstract][Full Text] [Related]
16. Clinical development of antisense oligonucleotides as anti-cancer therapeutics. Chen HX Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768 [No Abstract] [Full Text] [Related]
17. Antisense anticancer oligonucleotide therapeutics. Wang H; Prasad G; Buolamwini JK; Zhang R Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878 [TBL] [Abstract][Full Text] [Related]
18. Antisense approaches to cancer gene therapy. Mercola D; Cohen JS Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254 [TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides: a new therapeutic approach. Temsamani J; Guinot P Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101 [TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical experience of antisense therapy for solid tumors. Webb MS; Zon G Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]